fbpx

Dr. Reddy’s Laboratories Announces the Launch of Levetiracetam in Sodium Chloride Injection in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
announced today that it has launched Levetiracetam in Sodium Chloride
Injection, 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and
1,500 mg/100 mL (15 mg/mL) single-dose infusion bags, a therapeutic
equivalent generic version of HQ Specialty Pharma Corporation’s
Levetiracetam in Sodium Chloride Injection, approved by the U.S. Food
and Drug Administration (USFDA).

The Levetiracetam in Sodium Chloride Injection brand and generic had
U.S. sales of approximately $37 million MAT for the most recent twelve
months ending in April 2018 according to IMS Health*.

Dr. Reddy’s Levetiracetam in Sodium Chloride Injection is available in
strengths of 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and
1,500 mg/100 mL (15 mg/mL) single-dose infusion bags.

*IMS National Sales Perspective: Retail and Non-Retail MAT April 2018RDY-0618-206

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier
lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy’s operates in markets across the globe. Our major markets
include – USA, India, Russia & CIS countries, and Europe. For more
information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may”, “will”, “should”, “expects”,
“plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”,
“potential”, or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults , currency exchange rates , interest
rates , persistency levels and frequency / severity of insured loss
events (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.

The company assumes no obligation to update any information contained
herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180619005572/en/